accountEli Lilly (NYSE: LLY) jumped on the oral-drug-for-rheumatoid-arthritis bandwagon yesterday. Joining Pfizer (NYSE: PFE), Rigel Pharmaceuticals, and Lexicon Pharmaceuticals, Eli Lilly licensed a phase 2 drug, INCB28050, from Incyte (Nasdaq: INCY...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Some Incyte Into Why These Drugs Rock
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account